Innovotech Inc (IOT) - Total Assets
Based on the latest financial reports, Innovotech Inc (IOT) holds total assets worth CA$4.43 Million CAD (≈ $3.21 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See shareholders equity of Innovotech Inc for net asset value and shareholders' equity analysis.
Innovotech Inc - Total Assets Trend (2003–2025)
This chart illustrates how Innovotech Inc's total assets have evolved over time, based on quarterly financial data.
Innovotech Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Innovotech Inc's total assets of CA$4.43 Million consist of 68.2% current assets and 31.8% non-current assets.
| Asset Category | Amount (CAD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CA$0.00 | 36.5% |
| Accounts Receivable | CA$507.64K | 11.5% |
| Inventory | CA$185.45K | 4.2% |
| Property, Plant & Equipment | CA$0.00 | 0.0% |
| Intangible Assets | CA$474.53K | 10.7% |
| Goodwill | CA$0.00 | 0.0% |
Asset Composition Trend (2003–2025)
This chart illustrates how Innovotech Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see how much is Innovotech Inc worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Innovotech Inc's current assets represent 68.2% of total assets in 2025, a decrease from 91.3% in 2003.
- Cash Position: Cash and equivalents constituted 36.5% of total assets in 2025, down from 90.0% in 2003.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 10.0% of total assets, an increase from 0.0% in 2003.
- Asset Diversification: The largest asset category is accounts receivable at 11.5% of total assets.
Innovotech Inc Competitors by Total Assets
Key competitors of Innovotech Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Sagimet Biosciences Inc. Series A Common Stock
NASDAQ:SGMT
|
USA | $107.75 Million |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND
|
USA | $1.53 Billion |
|
Inner Mongolia Furui Med Sci
SHE:300049
|
China | CN¥3.42 Billion |
|
Bio-Thera Solutions Ltd
SHG:688177
|
China | CN¥2.39 Billion |
|
Wuhan Keqian Biology Co Ltd
SHG:688526
|
China | CN¥4.75 Billion |
|
Gubra A/S
CO:GUBRA
|
Denmark | Dkr1.32 Billion |
Innovotech Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.79 | 3.98 | 4.90 |
| Quick Ratio | 5.43 | 3.68 | 4.65 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CA$2.50 Million | CA$1.26 Million | CA$617.22K |
Innovotech Inc - Advanced Valuation Insights
This section examines the relationship between Innovotech Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.18 |
| Latest Market Cap to Assets Ratio | 1.07 |
| Asset Growth Rate (YoY) | 37.7% |
| Total Assets | CA$4.43 Million |
| Market Capitalization | $4.73 Million USD |
Valuation Analysis
Above Book Valuation: The market values Innovotech Inc's assets above their book value (1.07x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: Innovotech Inc's assets grew by 37.7% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Innovotech Inc (2003–2025)
The table below shows the annual total assets of Innovotech Inc from 2003 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CA$4.43 Million ≈ $3.21 Million |
+37.67% |
| 2024-12-31 | CA$3.22 Million ≈ $2.33 Million |
+164.68% |
| 2023-12-31 | CA$1.22 Million ≈ $880.02K |
-0.51% |
| 2022-12-31 | CA$1.22 Million ≈ $884.56K |
-14.67% |
| 2021-12-31 | CA$1.43 Million ≈ $1.04 Million |
+74.23% |
| 2020-12-31 | CA$822.44K ≈ $594.94K |
+199.20% |
| 2019-12-31 | CA$274.88K ≈ $198.85K |
+0.94% |
| 2018-12-31 | CA$272.33K ≈ $197.00K |
-48.35% |
| 2017-12-31 | CA$527.26K ≈ $381.42K |
+62.10% |
| 2016-12-31 | CA$325.27K ≈ $235.30K |
+52.66% |
| 2015-12-31 | CA$213.06K ≈ $154.13K |
-47.89% |
| 2014-12-31 | CA$408.86K ≈ $295.76K |
-3.39% |
| 2013-12-31 | CA$423.21K ≈ $306.14K |
-49.54% |
| 2003-12-31 | CA$838.70K ≈ $606.70K |
-4.87% |
| 2003-09-30 | CA$881.62K ≈ $637.75K |
-- |
About Innovotech Inc
Innovotech Inc. provides assay kits used in growing microbial biofilms for research purposes in Canada, the United States, and internationally. The company offers InnovoSIL, a silver periodate antimicrobial compounds for medical applications; and MBEC Assay kit, a screening assay used to determine the efficacy of antimicrobials against biofilms of a variety of microorganisms; pre-coated MBEC Assa… Read more